Related Experiment Video
Updated: Apr 30, 2026
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR
Kevin P Nikitczuk1, Edmund C Lattime2, Rene S Schloss1
1Department of Biomedical Engineering, Rutgers University, 599 Taylor Road Piscataway, New Jersey, USA.
Insights
1-Methyl-Tryptophan (1 MT) delivered via nanopolymers enhances dendritic cell (DC) activation and promotes a Th1 immune response. This approach, combining 1 MT with antigen and adjuvant, optimizes DC function for immunotherapy.
Area of Science:
- Immunology
- Nanotechnology
- Biochemistry
Background:
- Dendritic cells (DCs) are crucial for immune modulation, but their activation mechanisms require further understanding for immunotherapy optimization.
- DCs paradoxically secrete immune-suppressive indoleamine 2,3-dioxygenase (IDO) and IL-10, complicating their therapeutic use.
- 1-Methyl-Tryptophan (1 MT) inhibits IDO, but its broader effects on DCs, especially in therapeutic contexts, are understudied.
Purpose of the Study:
- To investigate the effects of 1 MT on dendritic cell activation beyond IDO inhibition.
- To evaluate the efficacy of a nanopolymer-based delivery system for 1 MT, antigen (OVA), and adjuvant (CpG).
- To determine how 1 MT influences DC stimulation and subsequent immune responses when delivered via nanopolymers.
Main Methods:
- Administered 1 MT using a nanopolymer delivery system combined with ovalbumin (OVA) and CpG adjuvant.
- Assessed DC activation by measuring surface markers (CD80, CD86, MHCII) and secreted cytokines (IL-12, IL-10).
- Compared nanopolymer delivery with soluble delivery of the same components.
Main Results:
- 1 MT alone, whether in solution or via nanopolymer, did not significantly alter DC activation markers or IL-12 secretion.
- 1 MT combined with OVA and CpG upregulated DC activation markers and IL-12 secretion, with nanopolymer delivery showing a differential effect.
- Nanopolymer delivery of 1 MT, OVA, and CpG resulted in lower IL-10 secretion and increased IL-12 secretion compared to soluble delivery.
Conclusions:
- Nanopolymer-based delivery of 1 MT, OVA, and CpG enhances DC stimulation and promotes a Th1-type immune response.
- Supplementing nanopolymer formulations with 1 MT shifts DCs towards an immune-enhancing profile.
- This strategy offers a promising approach for optimizing DC function in immunotherapy.
Abstract:
Dendritic cells (DCs) play a pivotal role in immune modulation. Therefore, understanding and regulating the mechanism of DC activation is paramount for functional optimization of any immunotherapy strategy. In particular, the paradoxical ability of DCs to secrete the immune suppressive enzyme indoleamine 2, 3-dioxygenase (IDO) and the suppressive cytokine IL-10 during the course of, and in response to, stimulation is of great interest. 1-Methyl-Tryptophan (1 MT) is a known inhibitor of IDO and has thus been administered in numerous in vitro and in vivo systems to block IDO activity. However, the effect 1 MT has on DCs beyond inhibiting IDO, especially in therapeutic models, has rarely been analyzed. In the current study, we have administered 1 MT via a nanopolymer-based delivery system in conjunction with an antigen (ovalbumin, OVA) and an adjuvant (CpG motif DNA) to determine both the effects of 1 MT on DCs and the resulting efficacy of the polymer-based treatments. 1 MT delivery alone, either via the polymer-based delivery vehicle or dissolved in solution, induced no significant change in DC activation as measured by surface expression of CD80, CD86, and MHCII and several secreted products such as IL-12. These same factors were upregulated however, when 1 MT was delivered in conjunction with OVA and CpG. Although soluble delivery of these components increased the levels of expression and secretion of key proteins, a differential effect of DC stimulation was seen as a result of the polymer delivery system. The T cell suppressive IL-10 secretion was lower with the polymer-based treatments and IL-12 immune-enhancing secretion was increased when 1 MT was supplemented into the polymer system. As a result, including 1 MT in the polymers along with OVA and CpG was seen to have additional effects on DC stimulation and was able to shift DCs to a state more indicative of inducing a Th1-type response.
